Education
About Us
Working with TipRanks
Follow Us
Teladoc (TDOC)
NYSE:TDOC
Top Page
Teladoc
(NYSE:TDOC)
48Neutral
Positive Factors
Financial Performance
Teladoc's revenue and adjusted EBITDA came in ahead of expectations, providing comfort that the company is progressing in line with expectations.
Strategic Acquisitions
Higher levels of connectivity to payors via the UpLift acquisition offer a potential avenue out of the less-stable cash pay market and into the more-stable insurance market.
Negative Factors
Revenue Growth
Average revenue per US Integrated Care Member fell 8.6% sequentially and 8.0% year-over-year, which could impact overall revenue growth.
Segment Performance
BetterHelp sales fell 11% from the prior-year period with adjusted EBITDA down 50% year-over-year.
Teladoc (TDOC) vs. S&P 500 (SPY)
Market Cap
$1.24B
Dividend YieldN/A
Average Volume (3M)5.66M
Price to Earnings (P/E)―
Beta (1Y)1.34
Revenue Growth-2.54%
EPS Growth-322.03%
CountryUS
Employees4,620
SectorHealthcare
Sector Strength56
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.53
Shares Outstanding175,434,770
10 Day Avg. Volume6,213,257
30 Day Avg. Volume5,660,192
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.43
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.97
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$9.59Price Target Upside35.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering21
Teladoc Business Overview & Revenue Model
Company DescriptionTeladoc Health, Inc. (TDOC) is a leading provider of virtual healthcare services, operating primarily in the telemedicine sector. The company offers a broad range of virtual care solutions, including telehealth consultations, mental health services, and expert medical services. Teladoc's platform connects patients with licensed healthcare professionals via video, phone, or app-based interactions, allowing for convenient and accessible medical care.
How the Company Makes MoneyTeladoc generates revenue primarily through a subscription-based model, where individuals or organizations pay for access to its virtual healthcare services. Key revenue streams include membership fees from health plans, employers, and individual users who subscribe to its telemedicine services. Additionally, the company earns income from fees charged per virtual visit, which are paid by health plans or directly by patients. Significant partnerships with healthcare providers, insurance companies, and employers enhance its market reach and contribute to its earnings. Teladoc also offers specialized services and second opinion consultations, which further diversify its revenue sources.
Teladoc Key Performance Indicators (KPIs)
Any
US Integrated Care Members
Tracks the number of members using Teladoc's integrated care services in the US, indicating market penetration and potential for cross-selling additional services.
Tracks the number of members using Teladoc's integrated care services in the US, indicating market penetration and potential for cross-selling additional services.
Data provided by:
Main Street Data
Main Street DataTeladoc Financial Statement Overview
Summary
Teladoc faces challenges with fluctuating revenue growth and ongoing losses reflected in negative net profit margins. However, stable gross profit margins and positive free cash flow indicate some financial strengths and improvement potential.Income Statement
Teladoc has shown fluctuating revenue growth, with a decline from 2023 to the TTM period. The gross profit margin is stable at around 66-67%, but the net profit margin remains negative, indicating ongoing losses. EBIT and EBITDA margins are also negative, reflecting operational challenges.―
Balance Sheet
The debt-to-equity ratio is relatively high, suggesting considerable leverage, but the equity ratio demonstrates a stable equity base. The ROE remains negative due to continuous net losses, which indicates profitability concerns.55
Cash Flow
Free cash flow has been positive in the TTM period, showing signs of improvement. The operating cash flow to net income ratio is favorable, suggesting a good cash conversion from operations despite negative net income.―
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 2.57B | 2.60B | 2.41B | 2.03B | 1.09B | Gross Profit |
| 1.82B | 1.84B | 1.66B | 1.38B | 703.13M | EBIT |
| -1.02B | -248.55M | 13.20B | -238.99M | -418.19M | EBITDA |
| -587.01M | 154.00M | -13.38B | -84.67M | -438.01M | Net Income Common Stockholders |
| -1.00B | -220.37M | -13.66B | -428.79M | -485.14M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 1.30B | 1.12B | 918.18M | 896.02M | 786.57M | Total Assets |
| 3.52B | 4.39B | 4.35B | 17.73B | 17.76B | Total Debt |
| 1.58B | 1.59B | 1.57B | 1.27B | 1.47B | Net Debt |
| 286.29M | 468.60M | 655.15M | 373.96M | 731.97M | Total Liabilities |
| 2.03B | 2.07B | 2.04B | 1.69B | 1.87B | Stockholders Equity |
| 1.49B | 2.33B | 2.31B | 16.05B | 15.88B |
| Cash Flow | Free Cash Flow | |||
| 282.89M | 193.67M | 16.53M | 130.06M | -79.55M | Operating Cash Flow |
| 293.68M | 350.02M | 189.29M | 193.99M | -53.51M | Investing Cash Flow |
| -124.05M | -156.35M | -167.74M | -72.98M | -590.98M | Financing Cash Flow |
| 8.31M | 10.85M | 6.50M | 40.95M | 859.14M |
Teladoc Technical Analysis
Negative
7.06
Price Trends
8.26
Negative
9.41
Negative
9.09
Negative
Market Momentum
-0.34
Negative
41.14
Neutral
56.93
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TDOC, the sentiment is Negative. The current price of 7.06 is below the 20-day moving average (MA) of 7.14, below the 50-day MA of 8.26, and below the 200-day MA of 9.09, indicating a bearish trend. The MACD of -0.34 indicates Negative momentum. The RSI at 41.14 is Neutral, neither overbought nor oversold. The STOCH value of 56.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TDOC.
Teladoc Risk Analysis
Teladoc disclosed 57 risk factors in its most recent earnings report. Teladoc reported the most risks in the “Ability to Sell” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Teladoc Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $1.49B | 14.72 | 10.79% | 2.54% | 15.25% | 51.77% | |
58 Neutral | $1.40B | ― | -22.67% | ― | 17.83% | 59.64% | |
57 Neutral | $1.81B | ― | -113.76% | ― | 229.74% | 70.23% | |
52 Neutral | $5.35B | 3.81 | -42.57% | 2.86% | 17.10% | 1.33% | |
50 Neutral | $1.86B | ― | -38.58% | ― | -4.21% | -544.81% | |
48 Neutral | $1.24B | ― | -54.49% | ― | -2.54% | -322.03% | |
36 Underperform | $1.01B | ― | -32.04% | ― | ― | 12.85% |
* Healthcare Sector Average
Performance Comparison
TDOC
Teladoc
7.06
-5.73
-44.80%
NHC
National Healthcare
96.18
5.08
5.58%
PHR
Phreesia
25.72
3.04
13.40%
ARQT
Arcutis Biotherapeutics
15.24
7.29
91.70%
SDGR
Schrodinger
25.29
1.24
5.16%
ELVN
Enliven Therapeutics
20.51
-2.41
-10.51%
Teladoc Earnings Call Summary
Earnings Call Date:Feb 24, 2026
(Q1-2025)
| % Change Since: -1.81%|
Next Earnings Date:Apr 29, 2026
Earnings Call Sentiment Neutral
The earnings call presented a mix of positive strategic developments such as the acquisition of UpLift, growth in the Integrated Care segment, and international success, but these were offset by financial challenges, including revenue decline, net losses, and macroeconomic concerns. The sentiment is balanced, reflecting both opportunities and challenges.Q1-2025 Updates
Positive Updates
Acquisition of UpLift
Teladoc Health announced the acquisition of UpLift, a virtual mental health company, to enhance its BetterHelp segment. UpLift is an in-network provider to health plans covering over 100 million lives, which aligns with Teladoc's strategic priorities.
Integrated Care Segment Growth
The Integrated Care segment saw revenue of $389.5 million, a 3.3% increase over the prior year, driven by U.S. virtual visit volume increase of 7% and chronic care enrollment growth of 3%.
International Business Success
Teladoc's international business in the Integrated Care segment grew with revenue increasing in the mid-teens on a constant currency basis.
Recognition for Trustworthiness
Teladoc was named to Newsweek's Most Trustworthy Companies in America for 2025 and ranked number one in the healthcare and life sciences industry.
Negative Updates
Revenue Decline
First quarter consolidated revenue was $629.4 million, down 3% year-over-year. BetterHelp segment revenue decreased by 11% compared to the prior year.
Net Loss Per Share
Consolidated net loss per share was $0.53, compared to a net loss per share of $0.49 in the first quarter of 2024, including a non-cash goodwill impairment charge.
Challenges in BetterHelp Segment
BetterHelp's adjusted EBITDA margin decreased from 5.7% to 3.2%, and average paying users declined slightly. There were increased member churn rates noted.
Macroeconomic and Tariff Concerns
The broader economic environment and potential $5 million to $10 million tariff impact pose challenges, particularly with the fluidity of the situation.
Company Guidance
During the Teladoc Health First Quarter 2025 Earnings Call, significant guidance was provided concerning financial performance and strategic initiatives. The company reported consolidated revenue of $629.4 million, with adjusted EBITDA of $58.1 million, both at the higher end of guidance ranges. The BetterHelp segment saw a revenue of $239.9 million and an adjusted EBITDA margin of 3.2%. For full-year 2025, Teladoc expects revenue between $2.47 billion and $2.58 billion, with an adjusted EBITDA range of $263 million to $304 million. The recent acquisition of UpLift is anticipated to contribute approximately $10 million in incremental revenue in 2025, with potential increased member durations and conversion rates due to benefits coverage. The company is also focusing on technology improvements and international expansion to drive growth. Despite uncertainties in the macroeconomic environment, Teladoc emphasized its strategic priorities to expand access to virtual mental health services and leverage its scale in integrated care and BetterHelp segments.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.